MCID: PNC129
MIFTS: 65

Pancreatic Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Adenocarcinoma

MalaCards integrated aliases for Pancreatic Adenocarcinoma:

Name: Pancreatic Adenocarcinoma 12 29 6 15 17
Adenocarcinoma of the Pancreas 12
Adenocarcinoma of Pancreas 70
Pancreas Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4074
NCIt 50 C8294
SNOMED-CT 67 700423003
UMLS 70 C0281361

Summaries for Pancreatic Adenocarcinoma

Disease Ontology : 12 A pancreatic carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Pancreatic Adenocarcinoma, also known as adenocarcinoma of the pancreas, is related to pancreatic ductal adenocarcinoma and adenocarcinoma, and has symptoms including abdominal pain, pruritus and icterus. An important gene associated with Pancreatic Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and HIV Life Cycle. The drugs Ethanol and Propofol have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lymph node and endothelial, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Pancreatic Adenocarcinoma

Diseases related to Pancreatic Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 675)
# Related Disease Score Top Affiliating Genes
1 pancreatic ductal adenocarcinoma 32.8 TP53 SMAD4 KRAS ERBB2 EGFR CTNNB1
2 adenocarcinoma 32.4 TP53 SMAD4 POLE PIK3CA MUC4 KRAS
3 pancreatic cancer 32.3 TP53 SMAD4 PIK3CA MUC4 MAP2K2 KRAS
4 exanthem 31.3 KRAS HRAS ERBB2 EGFR
5 pancreas disease 31.2 U2AF1 TP53 KRAS HRAS
6 hereditary breast ovarian cancer syndrome 31.2 TP53 KRAS HRAS ERBB2 CDKN2A
7 intrahepatic cholangiocarcinoma 31.1 TP53 SMAD4 MUC4 KRAS ERBB2 EGFR
8 pancreatic ductal carcinoma 31.1 TP53 SMAD4 ERBB2 EGFR CDKN2A
9 cholangiocarcinoma 31.1 TP53 SMAD4 PIK3CA MUC4 KRAS ERBB2
10 mucinous adenocarcinoma 31.1 TP53 KRAS ERBB2 EGFR CDKN2A
11 cystadenocarcinoma 31.0 TP53 PIK3CA HRAS ERBB2
12 adenoma 31.0 TP53 SMAD4 PIK3CA KRAS GNAS CTNNB1
13 peutz-jeghers syndrome 31.0 TP53 SMAD4 GNAS EGFR CTNNB1
14 appendix adenocarcinoma 30.9 SMAD4 KRAS HRAS GNAS
15 lynch syndrome 30.9 TP53 SMAD4 POLE PIK3CA KRAS HRAS
16 papilloma 30.9 TP53 KRAS ERBB2 EGFR CDKN2A
17 in situ carcinoma 30.9 TP53 PIK3CA HRAS ERBB2 EGFR CTNNB1
18 bile duct cancer 30.8 TP53 SMAD4 MUC4 KRAS HRAS ERBB2
19 gastrointestinal stromal tumor 30.8 TP53 KRAS ERBB2 EGFR CDKN2A
20 adenocarcinoma in situ 30.7 U2AF1 KRAS EGFR CDKN2A
21 biliary tract cancer 30.7 SMAD4 MUC4 ERBB2 EGFR
22 acinar cell carcinoma 30.7 TP53 SMAD4 CTNNB1
23 signet ring cell adenocarcinoma 30.7 TP53 KRAS HRAS ERBB2 CTNNB1
24 cholecystitis 30.7 TP53 MUC4 EGFR CDKN2A
25 colon adenoma 30.7 SMAD4 RXRA KRAS CTNNB1
26 familial adenomatous polyposis 30.7 TP53 SMAD4 KRAS HRAS CTNNB1
27 clear cell adenocarcinoma 30.7 TP53 SMAD4 PIK3CA
28 pseudomyxoma peritonei 30.7 TP53 KRAS GNAS CTNNB1
29 tubular adenocarcinoma 30.7 ERBB2 EGFR CTNNB1
30 gallbladder disease 30.7 TP53 KRAS HRAS ERBB2 EGFR CTNNB1
31 adenosquamous carcinoma 30.7 TP53 SMAD4 PIK3CA MUC4 KRAS EGFR
32 colon adenocarcinoma 30.6 TP53 SMAD4 PIK3CA KRAS ERBB2 EGFR
33 esophageal cancer 30.6 TP53 SMAD4 PIK3CA MUC4 LRRC56 KRAS
34 endometrial cancer 30.6 TP53 SMAD4 POLE PIK3CA KRAS HRAS
35 ovarian serous cystadenocarcinoma 30.6 TP53 PIK3CA LRRC56 KRAS HRAS GNAS
36 serous cystadenocarcinoma 30.6 TP53 POLE PIK3CA LRRC56 KRAS HRAS
37 melanoma 30.6 TP53 PIK3CA MAP2K2 LRRC56 KRAS HRAS
38 duodenum cancer 30.5 TP53 SMAD4 KRAS HRAS
39 breast adenocarcinoma 30.5 U2AF1 TP53 PIK3CA KRAS ERBB2 EGFR
40 sarcoma 30.5 TP53 PIK3CA KRAS HRAS CTNNB1
41 keratosis 30.5 TP53 PIK3CA HRAS CDKN2A
42 keratosis, seborrheic 30.5 TP53 PIK3CA CDKN2A
43 cervical adenocarcinoma 30.5 TP53 KRAS ERBB2 EGFR CDKN2A
44 teratoma 30.5 TP53 KRAS CTNNB1 CDKN2A
45 liposarcoma 30.5 TP53 PIK3CA CTNNB1 CDKN2A
46 biliary tract disease 30.5 TP53 KRAS HRAS EGFR CTNNB1
47 breast ductal carcinoma 30.5 TP53 SMAD4 ERBB2 EGFR CTNNB1
48 cervical squamous cell carcinoma 30.5 TP53 PIK3CA KRAS EGFR CTNNB1 CDKN2A
49 melanoma, cutaneous malignant 1 30.4 TP53 POLE HRAS CTNNB1 CDKN2A
50 colorectal adenocarcinoma 30.4 TP53 KRAS HRAS ERBB2 EGFR CTNNB1

Graphical network of the top 20 diseases related to Pancreatic Adenocarcinoma:



Diseases related to Pancreatic Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Adenocarcinoma

UMLS symptoms related to Pancreatic Adenocarcinoma:


abdominal pain; pruritus; icterus

GenomeRNAi Phenotypes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.57 EGFR HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.57 EGFR HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.57 KRAS
4 Decreased viability GR00106-A-0 10.57 KRAS
5 Decreased viability GR00221-A-1 10.57 EGFR HRAS KRAS PIK3CA CDKN2A RXRA
6 Decreased viability GR00221-A-2 10.57 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.57 HRAS CDKN2A
8 Decreased viability GR00221-A-4 10.57 EGFR PIK3CA CDKN2A
9 Decreased viability GR00249-S 10.57 RXRA
10 Decreased viability GR00301-A 10.57 KRAS
11 Decreased viability GR00381-A-1 10.57 KRAS RXRA
12 Decreased viability GR00402-S-2 10.57 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-104 10 MED12
14 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10 MED12
15 Increased shRNA abundance (Z-score > 2) GR00366-A-109 10 MYCN
16 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10 MED12
17 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10 KRAS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10 MYCN
19 Increased shRNA abundance (Z-score > 2) GR00366-A-153 10 MED12
20 Increased shRNA abundance (Z-score > 2) GR00366-A-165 10 MYCN
21 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10 MYCN
22 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10 MYCN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10 MED12
24 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10 MED12
25 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10 KRAS
26 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10 MED12
27 Increased shRNA abundance (Z-score > 2) GR00366-A-26 10 MED12
28 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10 MED12
29 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10 CTNNB1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10 PIK3CA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10 KRAS
32 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10 MED12
33 Increased shRNA abundance (Z-score > 2) GR00366-A-89 10 MED12
34 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10 MED12
35 Decreased cell migration GR00055-A-1 9.8 MAP2K2
36 Decreased cell migration GR00055-A-3 9.8 EGFR HRAS PIK3CA
37 Reduced mammosphere formation GR00396-S 9.17 EGFR GNAS HRAS KRAS POLE RXRA

MGI Mouse Phenotypes related to Pancreatic Adenocarcinoma:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.46 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
2 cellular MP:0005384 10.42 CDKN2A CTNNB1 EGFR ERBB2 GNAS KRAS
3 growth/size/body region MP:0005378 10.41 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
4 mortality/aging MP:0010768 10.4 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
5 homeostasis/metabolism MP:0005376 10.39 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
6 craniofacial MP:0005382 10.38 CTNNB1 EGFR ERBB2 GNAS HRAS KRAS
7 endocrine/exocrine gland MP:0005379 10.35 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
8 integument MP:0010771 10.35 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
9 digestive/alimentary MP:0005381 10.33 CDKN2A CTNNB1 EGFR ERBB2 HRAS KRAS
10 embryo MP:0005380 10.32 CDKN2A CTNNB1 EGFR ERBB2 KRAS MED12
11 neoplasm MP:0002006 10.27 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
12 muscle MP:0005369 10.26 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
13 nervous system MP:0003631 10.25 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
14 limbs/digits/tail MP:0005371 10.22 CTNNB1 EGFR ERBB2 GNAS KRAS MED12
15 liver/biliary system MP:0005370 10.16 CDKN2A CTNNB1 EGFR GNAS KRAS MYCN
16 normal MP:0002873 10.15 CTNNB1 EGFR ERBB2 GNAS HRAS KRAS
17 hearing/vestibular/ear MP:0005377 10.1 CTNNB1 EGFR GNAS KRAS MAP2K2 RXRA
18 no phenotypic analysis MP:0003012 10.06 CDKN2A CTNNB1 EGFR GNAS HRAS KRAS
19 renal/urinary system MP:0005367 9.91 CTNNB1 EGFR GNAS HRAS KRAS MYCN
20 reproductive system MP:0005389 9.9 CDKN2A CTNNB1 EGFR ERBB2 KRAS LRRC56
21 pigmentation MP:0001186 9.8 CDKN2A CTNNB1 EGFR KRAS RXRA TP53
22 respiratory system MP:0005388 9.65 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS
23 skeleton MP:0005390 9.47 CDKN2A CTNNB1 EGFR ERBB2 GNAS HRAS

Drugs & Therapeutics for Pancreatic Adenocarcinoma

Drugs for Pancreatic Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 281)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Desflurane Approved Phase 4 57041-67-5 42113
4 Anesthetics Phase 4
5 Anesthetics, General Phase 4
6 Anesthetics, Inhalation Phase 4
7
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
8
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
10
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 209810-58-2, 11096-26-7
11
tannic acid Approved Phase 3 1401-55-4
12
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
13
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
14
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
15
Irinotecan Approved, Investigational Phase 2, Phase 3 100286-90-6, 97682-44-5 60838
16
leucovorin Approved Phase 2, Phase 3 58-05-9 6006
17
Capecitabine Approved, Investigational Phase 2, Phase 3 154361-50-9 60953
18
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
19
Gemcitabine Approved Phase 3 95058-81-4 60750
20
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
21
Dalteparin Approved Phase 3 9005-49-6
22
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
23
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
24
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
25
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
26
Rubitecan Investigational Phase 3 91421-42-0
27
Irofulven Investigational Phase 3 158440-71-2
28 ON 01910 Phase 3
29 Hematinics Phase 3
30
asparaginase Phase 3
31 Tubulin Modulators Phase 2, Phase 3
32 Antimitotic Agents Phase 2, Phase 3
33 Albumin-Bound Paclitaxel Phase 2, Phase 3
34 Vitamin B9 Phase 2, Phase 3
35 Vitamin B Complex Phase 2, Phase 3
36 Folate Phase 2, Phase 3
37 Protective Agents Phase 2, Phase 3
38 Liver Extracts Phase 2, Phase 3
39 Antidotes Phase 2, Phase 3
40 Immunologic Factors Phase 3
41 Antiviral Agents Phase 3
42 Antimetabolites Phase 3
43 Anticoagulants Phase 3
44 Fibrinolytic Agents Phase 3
45 Heparin, Low-Molecular-Weight Phase 3
46 calcium heparin Phase 3
47
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
48
Melphalan Approved Phase 2 148-82-3 4053 460612
49
Lenograstim Approved, Investigational Phase 2 135968-09-1
50
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150

Interventional clinical trials:

(show top 50) (show all 677)
# Name Status NCT ID Phase Drugs
1 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Unknown status NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
2 A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
3 Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? Completed NCT02335151 Phase 4 Desflurane
4 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
5 A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
6 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
7 A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Withdrawn NCT03891979 Phase 4 Pembrolizumab;Ciprofloxacin 500mg PO BID days 1-29;Metronidazole 500mg PO TID days 1-29
8 Phase III Randomized Study Of Gemcitabine Versus Gemcitabine-Oxaliplatine In Patients With Locally Advanced Or Metastatic Pancreatic Carcinoma Unknown status NCT00075452 Phase 3 gemcitabine hydrochloride;oxaliplatin
9 Phase II Randomisee Dans Les Adenocarcinomes Metastatiques Du Pancreas: Gemox Et Gemox Simplifie. [GEMOX] Unknown status NCT00268411 Phase 3 gemcitabine hydrochloride;oxaliplatin
10 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus 5-Fluorouracil (5-FU) in Pancreatic Cancer Patients That Have Progressive Disease Following Gemcitabine HCl Treatment Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan
11 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients Unknown status NCT00005870 Phase 3 fluorouracil;gemcitabine hydrochloride;mitomycin C;rubitecan
12 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients Unknown status NCT00005869 Phase 3 gemcitabine hydrochloride;rubitecan
13 Phase III Randomized, Double-blind Study Comparing Gemcitabine and Sorafenib or a Placebo in Patients With Locally Advanced or Metastatic Cancer of the Pancreas. Unknown status NCT00541021 Phase 3 gemcitabine hydrochloride;sorafenib tosylate
14 A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen Unknown status NCT00088660 Phase 3
15 A Randomized Two-armed Open Study on the Adjuvant Therapy in Patients With R0/R1 Resected Pancreatic Carcinoma With Gemcitabine Plus Capecitabine (Arm GC) vs. Gemcitabine Plus Cisplatin With Regional Hyperthermia (Arm GPH) Unknown status NCT01077427 Phase 3 Gemcitabine + Capecitabine
16 Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
17 A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma Completed NCT00003216 Phase 3 fluorouracil;gemcitabine hydrochloride
18 Randomized Phase II-III Trial of Post-operative Treatment of Pancreatic Adenocarcinoma: Gemcitabine Versus PEFG Followed by Radiochemotherapy With Concomitant Continuous Infusion of 5-fluorouracil Completed NCT00960284 Phase 2, Phase 3 capecitabine;cisplatin;epirubicin hydrochloride;fluorouracil;gemcitabine hydrochloride
19 Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients Completed NCT00112658 Phase 2, Phase 3 fluorouracil;gemcitabine hydrochloride;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
20 An Open Label, Randomized, Controlled, Phase III, Multi-center, Clinical Trial Of PN401 With High Dose 5-Fluorouracil (5FU) Versus Gemcitabine For Treatment Of Patients With Advanced Pancreatic Cancer Completed NCT00024427 Phase 3 fluorouracil;gemcitabine hydrochloride;triacetyluridine
21 Non Resectable But Non Metastatic Adenocarcinoma of the Exocrine Pancreas Non Resecables. Randomised Phase III: Initial Radiochimiotherapy (5-FU, Cisplatine, 60 GY Radiotherapy) Followed by Gemcitabine Versus Gemcitabine Alone Completed NCT00416507 Phase 3 fluorouracil;gemcitabine hydrochloride;liposomal cisplatin
22 A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Completed NCT00058149 Phase 3 gemcitabine hydrochloride;oxaliplatin
23 A Randomized Phase III Study Of Gemcitabine In Combination With Radiation Therapy Versus Gemcitabine Alone In Patients With Localized, Unresectable Pancreatic Cancer Completed NCT00057876 Phase 3 Gemcitabine
24 Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression Completed NCT00303758 Phase 3 cisplatin;fluorouracil;gemcitabine hydrochloride;leucovorin calcium
25 A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer Completed NCT00075686 Phase 3 gemcitabine hydrochloride
26 Randomized Phase II/III Study Comparing Gemcitabine Followed by Gemcitabine Plus Concomitant Radiation (50.4 Gy) Versus Control After Curative Pancreaticoduodenectomy for Pancreatic Head Cancer Completed NCT00064207 Phase 2, Phase 3 gemcitabine hydrochloride
27 Gemcitabine Plus Capecitabine Versus Gemcitabine Alone In Advanced Pancreatic Cancer. A Randomized Phase III Trial Completed NCT00030732 Phase 3 Gemcitabine + Capecitabine;Gemcitabine alone
28 A Randomized Placebo Controlled Study Of OSI-774 (TARCEVA) Plus Gemcitabine In Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer Completed NCT00026338 Phase 3 erlotinib hydrochloride;gemcitabine hydrochloride
29 A Prospective, Randomized Trial of Extended Lymphadenectomy in the Management of Resectable Pancreatic Cancer Completed NCT00003049 Phase 3 fluorouracil;leucovorin calcium
30 Infusional 5-Fluorouracil With or Without Cisplatin and With or Without Chronomodulation Against Locally-Advanced or Metastatic Pancreatic Cancer. A Multicenter Randomized Phase III Trial. Completed NCT00003029 Phase 3 cisplatin;fluorouracil
31 Randomized Multicenter Phase III Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas: Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib. Intergroup Study Completed NCT00634725 Phase 3 capecitabine;erlotinib hydrochloride;gemcitabine hydrochloride
32 A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC#704865 IND#7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer Completed NCT00088894 Phase 3 gemcitabine hydrochloride
33 Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas (Protocol No. PC4) Completed NCT00044031 Phase 3
34 A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas Completed NCT00844649 Phase 3 Albumin-bound paclitaxel (ABI-007);Gemcitabine
35 A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer Completed NCT01360853 Phase 3 ON 01910.Na;Gemcitabine;Gemcitabine
36 A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma Completed NCT02436668 Phase 3 Ibrutinib;Gemcitabine;Nab-paclitaxel
37 A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed NCT01746979 Phase 3 TH-302;Gemcitabine;Placebo (5 percent dextrose - D5W)
38 Phase III Trial Of Irofulven Vs. 5-Fluorouracil In Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma Completed NCT00033735 Phase 3 fluorouracil;Irofulven
39 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Completed NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
40 A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine Completed NCT00099294 Phase 3 Glufosfamide
41 Phase II/III of Randomized Controlled Clinical Research on Irreversible Electroporation Synchronous Chemotherapy for Locally Advanced Pancreatic Adenocarcinoma Recruiting NCT03673137 Phase 2, Phase 3 Gemcitabine
42 Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. Recruiting NCT02072616 Phase 3
43 Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma Recruiting NCT03377491 Phase 3 Gemcitabine;nab paclitaxel
44 An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas Recruiting NCT04083235 Phase 3 Irinotecan Liposomal Injection;Oxaliplatin;5Fluorouracil;Leucovorin;Nab-paclitaxel;Gemcitabine
45 A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment Recruiting NCT03126435 Phase 3 EndoTAG-1;Gemcitabine
46 A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine Recruiting NCT01954992 Phase 3 Glufosfamide;Fluorouracil
47 Intrabdominal Hyperthermic Chemotherapy Using Gemcitabine to Treat Pancreatic Carcinomatosis Recruiting NCT03251365 Phase 2, Phase 3 HIPEC-gemcitabine
48 Randomized Phase 3 Trial Comparing FOLFOX to Gemcitabine in Metastatic First-line in Patients With Pancreatic Adenocarcinoma and Non-fit for FOLFIRINOX Recruiting NCT04167007 Phase 3 Gemcitabine;FOLFOX
49 A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma Recruiting NCT03899636 Phase 3 Modified FOLFIRINOX Regimen
50 A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas Active, not recruiting NCT03504423 Phase 3 CPI 613, mFolfirinox;Folfirinox

Search NIH Clinical Center for Pancreatic Adenocarcinoma

Genetic Tests for Pancreatic Adenocarcinoma

Genetic tests related to Pancreatic Adenocarcinoma:

# Genetic test Affiliating Genes
1 Pancreatic Adenocarcinoma 29

Anatomical Context for Pancreatic Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Adenocarcinoma:

40
Pancreas, Lymph Node, Endothelial, T Cells, Liver, Colon, Neutrophil

Publications for Pancreatic Adenocarcinoma

Articles related to Pancreatic Adenocarcinoma:

(show top 50) (show all 7540)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
2
Downregulation of long non-coding RNA LINC00460 inhibits the proliferation, migration and invasion, and promotes apoptosis of pancreatic cancer cells via modulation of the miR-320b/ARF1 axis. 61
33345740 2021
3
Myelodysplastic Syndrome in Patients with Gastro-Pancreatic Malignancies: A Case Series and Review of Literature. 61
32685937 2021
4
FUBP1 mediates the growth and metastasis through TGFβ/Smad signaling in pancreatic adenocarcinoma. 61
33649780 2021
5
Increased expression of zinc transporter ZIP4, ZIP11, ZnT1, and ZnT6 predicts poor prognosis in pancreatic cancer. 61
33631610 2021
6
Double cystic brain metastasis in a patient with stable pancreatic intraductal papillary mucinous neoplasm. 61
29557198 2021
7
Single-Pass vs 2-Pass Endoscopic Ultrasound-Guided Fine-Needle Biopsy Sample Collection for Creation of Pancreatic Adenocarcinoma Organoids. 61
32119924 2021
8
Forecasting sensitive targets of the kynurenine pathway in pancreatic adenocarcinoma using mathematical modeling. 61
33523522 2021
9
Anaplastic lymphoma kinase inhibitor NVP‑TAE684 suppresses the proliferation of human pancreatic adenocarcinoma cells. 61
33649854 2021
10
Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review. 61
33664810 2021
11
Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy. 61
32974690 2021
12
Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis. 61
33607382 2021
13
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. 61
33011748 2021
14
The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling. 61
33794773 2021
15
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study. 61
33452559 2021
16
Does Major Pancreatic Surgery Have Utility in Nonagenarians with Pancreas Cancer? 61
33141373 2021
17
Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma. 61
33808692 2021
18
Side-by-side comparison of next-generation sequencing, cytology, and histology in diagnosing locally advanced pancreatic adenocarcinoma. 61
32640200 2021
19
Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. 61
33772154 2021
20
Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis. 61
33808757 2021
21
Pancreatitis, panniculitis, and polyarthritis syndrome complicated with terminal pancreatic adenocarcinoma managed with intra-articular knee aspiration, intra-articular lidocaine and corticosteroid injection, and decompression of panniculitis: A case report. 61
33717781 2021
22
Myeloid sarcoma diagnosed on pleural effusion cytology: A case report and literature review. 61
33751858 2021
23
Association of Weight Change, Inflammation Markers and Disease Staging with Survival of Patients Undergoing Chemotherapy for Pancreatic Adenocarcinoma. 61
33749421 2021
24
Disparities in Stage-Specific Guideline-Concordant Cancer-Directed Treatment for Patients with Pancreatic Adenocarcinoma. 61
33768427 2021
25
Propensity score-matched comparison of the oncological feasibility and survival outcomes for pancreatic adenocarcinoma with robotic and open pancreatoduodenectomy. 61
33770276 2021
26
Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology. 61
33237353 2021
27
Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma. 61
33743485 2021
28
ASO Author Reflections: Tumor Biology and Safe Surgery Remain Major Determinants of Survival After Resection of Pancreatic Adenocarcinoma. 61
32880772 2021
29
Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma. 61
32077005 2021
30
Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma. 61
33465729 2021
31
Enteral Stents for Malignant Gastric Outlet Obstruction: Low Reintervention Rates for Obstruction due to Pancreatic Adenocarcinoma Versus Other Etiologies. 61
32077045 2021
32
Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy. 61
33398620 2021
33
Tumor-Stromal Interactions in a Co-Culture Model of Human Pancreatic Adenocarcinoma Cells and Fibroblasts and Their Connection with Tumor Spread. 61
33807441 2021
34
Fiducial-based image-guided SBRT for pancreatic adenocarcinoma: Does inter-and intra-fraction treatment variation warrant adaptive therapy? 61
33741015 2021
35
Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. 61
33674603 2021
36
High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial. 61
33667587 2021
37
Computed Tomography Perfusion Analysis of Pancreatic Adenocarcinoma using Deconvolution, Maximum Slope, and Patlak Methods - Evaluation of Diagnostic Accuracy and Interchangeability of Cut-Off Values. 61
33772484 2021
38
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. 61
33475684 2021
39
Thirty-day complication rates do not differ by race among patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. 61
33497474 2021
40
Fatty Pancreas: An Underappreciated Intersection of the Metabolic Profile and Pancreatic Adenocarcinoma. 61
33656378 2021
41
Agonistic CD40 Antibodies in Cancer Treatment. 61
33804039 2021
42
Geometric Reproducibility of Fiducial Markers and Efficacy of a Patient-Specific Margin Design Using Deep Inspiration Breath Hold for Stereotactic Body Radiation Therapy for Pancreatic Cancer. 61
33732963 2021
43
Chemoradiotherapy after curative surgery for locally advanced pancreatic cancer: A 20-year single center experience. 61
33285435 2021
44
CCL26 is upregulated by nab-paclitaxel in pancreatic cancer-associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K/AKT/mTOR pathway. 61
33764366 2021
45
Indole alkaloids from the leaves of Ravenia spectabilis engl. with activity against pancreatic cancer cell line. 61
33780702 2021
46
Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer. 61
33234234 2021
47
Genetic characteristics and prognostic implications of m1A regulators in pancreatic cancer. 61
33779693 2021
48
Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer. 61
33796412 2021
49
Use of volumetric CT scanning to predict tumor staging and survival in pancreatic cancer patients that are to be administered curative resection. 61
33684252 2021
50
Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. 61
30946073 2021

Variations for Pancreatic Adenocarcinoma

ClinVar genetic disease variations for Pancreatic Adenocarcinoma:

6 (show top 50) (show all 480)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MYCNOS , MYCN NM_005378.6(MYCN):c.131C>T (p.Pro44Leu) SNV Likely pathogenic 376460 rs1057519919 GRCh37: 2:16082317-16082317
GRCh38: 2:15942195-15942195
2 POLE NM_006231.3(POLE):c.857C>A (p.Pro286His) SNV Likely pathogenic 376502 rs1057519943 GRCh37: 12:133253184-133253184
GRCh38: 12:132676598-132676598
3 POLE NM_006231.3(POLE):c.856C>T (p.Pro286Ser) SNV Likely pathogenic 376501 rs1057519944 GRCh37: 12:133253185-133253185
GRCh38: 12:132676599-132676599
4 RXRA NM_002957.6(RXRA):c.1280C>A (p.Ser427Tyr) SNV Likely pathogenic 376529 rs1057519958 GRCh37: 9:137328351-137328351
GRCh38: 9:134436505-134436505
5 RXRA NM_002957.6(RXRA):c.1280C>T (p.Ser427Phe) SNV Likely pathogenic 376528 rs1057519958 GRCh37: 9:137328351-137328351
GRCh38: 9:134436505-134436505
6 POLE NM_006231.3(POLE):c.857C>G (p.Pro286Arg) SNV Likely pathogenic 376500 rs1057519943 GRCh37: 12:133253184-133253184
GRCh38: 12:132676598-132676598
7 MED12 NM_005120.3(MED12):c.3670C>G (p.Leu1224Val) SNV Likely pathogenic 376452 rs1057519912 GRCh37: X:70349258-70349258
GRCh38: X:71129408-71129408
8 ERBB2 NM_004448.3(ERBB2):c.2524G>A (p.Val842Ile) SNV Likely pathogenic 375994 rs1057519738 GRCh37: 17:37881332-37881332
GRCh38: 17:39725079-39725079
9 MED12 NM_005120.3(MED12):c.3670C>T (p.Leu1224Phe) SNV Likely pathogenic 376451 rs1057519912 GRCh37: X:70349258-70349258
GRCh38: X:71129408-71129408
10 PIK3CA NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr) SNV Likely pathogenic 376486 rs1057519937 GRCh37: 3:178952073-178952073
GRCh38: 3:179234285-179234285
11 PIK3CA NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu) SNV Likely pathogenic 376487 rs1057519936 GRCh37: 3:178952072-178952072
GRCh38: 3:179234284-179234284
12 PIK3CA NM_006218.4(PIK3CA):c.3127A>G (p.Met1043Val) SNV Likely pathogenic 376485 rs1057519936 GRCh37: 3:178952072-178952072
GRCh38: 3:179234284-179234284
13 MAP2K2 NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val) SNV Likely pathogenic 8273 rs121434498 GRCh37: 19:4117551-4117551
GRCh38: 19:4117553-4117553
14 PIK3CA NM_006218.4(PIK3CA):c.3129G>A (p.Met1043Ile) SNV Likely pathogenic 179173 rs121913283 GRCh37: 3:178952074-178952074
GRCh38: 3:179234286-179234286
15 PIK3CA NM_006218.4(PIK3CA):c.353G>A (p.Gly118Asp) SNV Likely pathogenic 156446 rs587777790 GRCh37: 3:178917478-178917478
GRCh38: 3:179199690-179199690
16 MAP2K2 NM_030662.3(MAP2K2):c.171T>G (p.Phe57Leu) SNV Likely pathogenic 376449 rs1057519910 GRCh37: 19:4117549-4117549
GRCh38: 19:4117551-4117551
17 TP53 NM_000546.5(TP53):c.701A>G (p.Tyr234Cys) SNV Likely pathogenic 127820 rs587780073 GRCh37: 17:7577580-7577580
GRCh38: 17:7674262-7674262
18 TP53 NM_000546.5(TP53):c.700T>C (p.Tyr234His) SNV Likely pathogenic 376691 rs864622237 GRCh37: 17:7577581-7577581
GRCh38: 17:7674263-7674263
19 CDKN2A NM_000077.4(CDKN2A):c.149A>G (p.Gln50Arg) SNV Likely pathogenic 232304 rs587778189 GRCh37: 9:21974678-21974678
GRCh38: 9:21974679-21974679
20 CDKN2A NM_058195.3(CDKN2A):c.194-3470G>T SNV Likely pathogenic 376384 rs1057519882 GRCh37: 9:21974677-21974677
GRCh38: 9:21974678-21974678
21 TP53 NM_000546.5(TP53):c.700T>G (p.Tyr234Asp) SNV Likely pathogenic 219759 rs864622237 GRCh37: 17:7577581-7577581
GRCh38: 17:7674263-7674263
22 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu) SNV Likely pathogenic 13653 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
23 U2AF1 NM_001025203.1(U2AF1):c.101C>T (p.Ser34Phe) SNV Likely pathogenic 376025 rs371769427 GRCh37: 21:44524456-44524456
GRCh38: 21:43104346-43104346
24 CTNNB1 NM_001904.4(CTNNB1):c.97T>A (p.Ser33Thr) SNV Likely pathogenic 376393 rs1057519886 GRCh37: 3:41266100-41266100
GRCh38: 3:41224609-41224609
25 TP53 NM_000546.5(TP53):c.742C>G (p.Arg248Gly) SNV Likely pathogenic 376652 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
26 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu) SNV Likely pathogenic 376655 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
27 TP53 NM_000546.5(TP53):c.706T>G (p.Tyr236Asp) SNV Likely pathogenic 142183 rs587782289 GRCh37: 17:7577575-7577575
GRCh38: 17:7674257-7674257
28 TP53 NM_000546.5(TP53):c.422G>A (p.Cys141Tyr) SNV Likely pathogenic 140801 rs587781288 GRCh37: 17:7578508-7578508
GRCh38: 17:7675190-7675190
29 TP53 NM_000546.5(TP53):c.536A>T (p.His179Leu) SNV Likely pathogenic 376608 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
30 TP53 NM_001276697.2(TP53):c.-26C>G SNV Likely pathogenic 376640 rs1057520000 GRCh37: 17:7578478-7578478
GRCh38: 17:7675160-7675160
31 HRAS , LRRC56 NM_005343.4(HRAS):c.182A>C (p.Gln61Pro) SNV Likely pathogenic 376322 rs121913233 GRCh37: 11:533874-533874
GRCh38: 11:533874-533874
32 TP53 NM_000546.5(TP53):c.613T>G (p.Tyr205Asp) SNV Likely pathogenic 376686 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
33 TP53 NM_000546.5(TP53):c.856G>A (p.Glu286Lys) SNV Likely pathogenic 183752 rs786201059 GRCh37: 17:7577082-7577082
GRCh38: 17:7673764-7673764
34 TP53 NM_000546.5(TP53):c.613T>C (p.Tyr205His) SNV Likely pathogenic 376685 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
35 TP53 NM_000546.5(TP53):c.818G>C (p.Arg273Pro) SNV Likely pathogenic 231060 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
36 TP53 NM_000546.5(TP53):c.404G>A (p.Cys135Tyr) SNV Likely pathogenic 141762 rs587781991 GRCh37: 17:7578526-7578526
GRCh38: 17:7675208-7675208
37 SMAD4 NM_005359.6(SMAD4):c.1081C>T (p.Arg361Cys) SNV Likely pathogenic 8543 rs80338963 GRCh37: 18:48591918-48591918
GRCh38: 18:51065548-51065548
38 TP53 NM_000546.5(TP53):c.452C>A (p.Pro151His) SNV Likely pathogenic 376639 rs1057520000 GRCh37: 17:7578478-7578478
GRCh38: 17:7675160-7675160
39 TP53 NM_000546.5(TP53):c.833C>A (p.Pro278His) SNV Likely pathogenic 376646 rs876659802 GRCh37: 17:7577105-7577105
GRCh38: 17:7673787-7673787
40 TP53 NM_000546.5(TP53):c.405C>G (p.Cys135Trp) SNV Likely pathogenic 376561 rs1057519976 GRCh37: 17:7578525-7578525
GRCh38: 17:7675207-7675207
41 TP53 NM_000546.5(TP53):c.577C>A (p.His193Asn) SNV Likely pathogenic 376614 rs876658468 GRCh37: 17:7578272-7578272
GRCh38: 17:7674954-7674954
42 TP53 NM_000546.5(TP53):c.824G>T (p.Cys275Phe) SNV Likely pathogenic 376582 rs863224451 GRCh37: 17:7577114-7577114
GRCh38: 17:7673796-7673796
43 TP53 NM_000546.6(TP53):c.821T>G SNV Likely pathogenic 376676 rs1057520006 GRCh37: 17:7577117-7577117
GRCh38: 17:7673799-7673799
44 TP53 NM_000546.5(TP53):c.577C>T (p.His193Tyr) SNV Likely pathogenic 230256 rs876658468 GRCh37: 17:7578272-7578272
GRCh38: 17:7674954-7674954
45 TP53 NM_000546.5(TP53):c.734G>A (p.Gly245Asp) SNV Likely pathogenic 12355 rs121912656 GRCh37: 17:7577547-7577547
GRCh38: 17:7674229-7674229
46 TP53 NM_000546.5(TP53):c.644G>A (p.Ser215Asn) SNV Likely pathogenic 376662 rs587782177 GRCh37: 17:7578205-7578205
GRCh38: 17:7674887-7674887
47 TP53 NM_000546.5(TP53):c.536A>C (p.His179Pro) SNV Likely pathogenic 376611 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
48 HRAS , LRRC56 NM_005343.4(HRAS):c.38G>T (p.Gly13Val) SNV Likely pathogenic 180848 rs104894226 GRCh37: 11:534285-534285
GRCh38: 11:534285-534285
49 CTNNB1 NM_001904.4(CTNNB1):c.121A>G (p.Thr41Ala) SNV Likely pathogenic 17580 rs121913412 GRCh37: 3:41266124-41266124
GRCh38: 3:41224633-41224633
50 TP53 NM_000546.5(TP53):c.487T>A (p.Tyr163Asn) SNV Likely pathogenic 376679 rs786203436 GRCh37: 17:7578443-7578443
GRCh38: 17:7675125-7675125

Expression for Pancreatic Adenocarcinoma

Search GEO for disease gene expression data for Pancreatic Adenocarcinoma.

Pathways for Pancreatic Adenocarcinoma

Pathways related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 132)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 TP53 SMAD4 MAP2K2 KRAS HRAS GNAS
2
Show member pathways
13.82 SMAD4 PIK3CA MUC4 MAP2K2 KRAS HRAS
3
Show member pathways
13.81 TP53 SMAD4 MAP2K2 KRAS HRAS GNAS
4
Show member pathways
13.79 TP53 SMAD4 RXRA MAP2K2 KRAS HRAS
5
Show member pathways
13.66 SMAD4 MAP2K2 KRAS HRAS GNAS ERBB2
6
Show member pathways
13.65 TP53 SMAD4 PIK3CA MAP2K2 KRAS HRAS
7
Show member pathways
13.61 SMAD4 RXRA PIK3CA MED12 MAP2K2 KRAS
8
Show member pathways
13.45 TP53 PIK3CA MAP2K2 KRAS HRAS ERBB2
9
Show member pathways
13.38 MAP2K2 KRAS HRAS GNAS ERBB2 EGFR
10
Show member pathways
13.32 TP53 MAP2K2 KRAS HRAS GNAS ERBB2
11
Show member pathways
13.31 TP53 SMAD4 RXRA PIK3CA MAP2K2 KRAS
12
Show member pathways
13.19 SMAD4 RXRA KRAS HRAS GNAS EGFR
13
Show member pathways
13.19 TP53 PIK3CA MAP2K2 KRAS HRAS EGFR
14
Show member pathways
13.17 TP53 MAP2K2 KRAS HRAS GNAS EGFR
15
Show member pathways
13.16 MAP2K2 KRAS HRAS GNAS EGFR CTNNB1
16
Show member pathways
13.1 TP53 MAP2K2 KRAS HRAS GNAS CTNNB1
17
Show member pathways
13.08 TP53 RXRA PIK3CA MAP2K2 KRAS HRAS
18
Show member pathways
13.06 TP53 PIK3CA MAP2K2 KRAS HRAS GNAS
19
Show member pathways
13.03 MAP2K2 KRAS HRAS GNAS EGFR CTNNB1
20
Show member pathways
13.03 PIK3CA MAP2K2 KRAS HRAS ERBB2 EGFR
21
Show member pathways
13.02 PIK3CA MAP2K2 KRAS HRAS ERBB2 EGFR
22
Show member pathways
12.99 PIK3CA MAP2K2 KRAS HRAS GNAS ERBB2
23
Show member pathways
12.94 PIK3CA MAP2K2 KRAS HRAS EGFR
24
Show member pathways
12.9 MAP2K2 KRAS HRAS GNAS CTNNB1
25 12.89 TP53 MAP2K2 KRAS HRAS ERBB2 EGFR
26
Show member pathways
12.87 PIK3CA MAP2K2 KRAS HRAS GNAS EGFR
27
Show member pathways
12.86 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
28
Show member pathways
12.85 TP53 PIK3CA MAP2K2 KRAS HRAS ERBB2
29
Show member pathways
12.84 TP53 PIK3CA MAP2K2 KRAS HRAS CDKN2A
30
Show member pathways
12.81 TP53 SMAD4 RXRA PIK3CA MAP2K2 KRAS
31
Show member pathways
12.8 PIK3CA MAP2K2 KRAS HRAS GNAS EGFR
32
Show member pathways
12.78 MAP2K2 KRAS HRAS GNAS EGFR
33
Show member pathways
12.78 TP53 MAP2K2 KRAS HRAS EGFR
34
Show member pathways
12.77 PIK3CA MAP2K2 KRAS HRAS GNAS EGFR
35
Show member pathways
12.76 TP53 RXRA PIK3CA MAP2K2 KRAS HRAS
36 12.75 PIK3CA MAP2K2 KRAS HRAS EGFR
37
Show member pathways
12.75 TP53 PIK3CA MAP2K2 KRAS HRAS ERBB2
38
Show member pathways
12.73 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
39
Show member pathways
12.72 PIK3CA MAP2K2 KRAS HRAS EGFR
40
Show member pathways
12.69 PIK3CA MAP2K2 HRAS GNAS EGFR
41 12.68 TP53 PIK3CA MAP2K2 KRAS HRAS ERBB2
42
Show member pathways
12.65 TP53 PIK3CA MAP2K2 KRAS HRAS ERBB2
43
Show member pathways
12.63 TP53 SMAD4 PIK3CA MAP2K2 KRAS HRAS
44
Show member pathways
12.62 MAP2K2 KRAS HRAS GNAS EGFR
45
Show member pathways
12.61 PIK3CA MAP2K2 KRAS HRAS ERBB2
46
Show member pathways
12.55 TP53 PIK3CA MAP2K2 KRAS HRAS ERBB2
47
Show member pathways
12.54 PIK3CA MAP2K2 KRAS HRAS EGFR
48
Show member pathways
12.54 PIK3CA MAP2K2 KRAS HRAS GNAS EGFR
49
Show member pathways
12.53 PIK3CA MAP2K2 KRAS HRAS CTNNB1
50
Show member pathways
12.53 PIK3CA MAP2K2 KRAS HRAS ERBB2 EGFR

GO Terms for Pancreatic Adenocarcinoma

Cellular components related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.9 U2AF1 TP53 SMAD4 SF3B2 RXRA POLE
2 nucleus GO:0005634 9.53 U2AF1 TP53 SMAD4 SF3B2 RXRA POLE
3 perinuclear region of cytoplasm GO:0048471 9.5 PIK3CA MAP2K2 HRAS GNAS ERBB2 EGFR

Biological processes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.19 TP53 SMAD4 RXRA MYCN MED12 ERBB2
2 negative regulation of cell proliferation GO:0008285 10 TP53 SMAD4 HRAS CTNNB1 CDKN2A
3 positive regulation of cell proliferation GO:0008284 9.97 MYCNOS KRAS HRAS ERBB2 EGFR CTNNB1
4 heart development GO:0007507 9.91 TP53 MED12 ERBB2 CTNNB1
5 negative regulation of gene expression GO:0010629 9.91 TP53 MYCN MAP2K2 HRAS CTNNB1
6 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 TP53 SMAD4 RXRA MYCN MED12 HRAS
7 MAPK cascade GO:0000165 9.88 MAP2K2 KRAS HRAS ERBB2 EGFR
8 positive regulation of protein phosphorylation GO:0001934 9.87 KRAS HRAS ERBB2 EGFR
9 positive regulation of gene expression GO:0010628 9.87 TP53 MYCN KRAS HRAS ERBB2 CTNNB1
10 cellular response to growth factor stimulus GO:0071363 9.77 ERBB2 EGFR CTNNB1
11 positive regulation of epithelial cell proliferation GO:0050679 9.73 HRAS ERBB2 EGFR
12 liver development GO:0001889 9.73 PIK3CA KRAS HRAS EGFR
13 Ras protein signal transduction GO:0007265 9.71 TP53 KRAS HRAS CDKN2A
14 positive regulation of MAP kinase activity GO:0043406 9.67 KRAS HRAS ERBB2 EGFR
15 ERBB2 signaling pathway GO:0038128 9.63 PIK3CA ERBB2 EGFR
16 positive regulation of transcription, DNA-templated GO:0045893 9.61 TP53 SMAD4 RXRA MYCN MED12 MAP2K2
17 response to isolation stress GO:0035900 9.58 KRAS HRAS
18 negative regulation of ERBB signaling pathway GO:1901185 9.55 ERBB2 EGFR
19 hair follicle placode formation GO:0060789 9.54 GNAS CTNNB1
20 negative regulation of immature T cell proliferation in thymus GO:0033088 9.52 ERBB2 CDKN2A
21 embryonic organ development GO:0048568 9.46 TP53 POLE MED12 CTNNB1
22 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 8.92 TP53 MYCN MAP2K2 EGFR

Molecular functions related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 10.01 POLE PIK3CA MAP2K2 KRAS HRAS GNAS
2 protein C-terminus binding GO:0008022 9.62 MED12 HRAS ERBB2 CTNNB1
3 RNA polymerase II transcription factor binding GO:0001085 9.43 TP53 SMAD4 CTNNB1
4 chromatin binding GO:0003682 9.43 TP53 SMAD4 POLE MED12 EGFR CTNNB1
5 MDM2/MDM4 family protein binding GO:0097371 9.37 TP53 CDKN2A
6 disordered domain specific binding GO:0097718 9.33 TP53 CTNNB1 CDKN2A
7 protein phosphatase binding GO:0019903 8.92 TP53 ERBB2 EGFR CTNNB1

Sources for Pancreatic Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....